Journal
CANCER LETTERS
Volume 342, Issue 1, Pages 139-149Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.08.043
Keywords
Glioblastoma; EGFR; Feedback loop; miR-21
Categories
Funding
- China National Natural Scientific Fund [81172406, 81101916]
- Research Fund for the Doctoral Program of Higher Education of China [20111202110004]
- Committee of Tianjin Science and Technology [12JCZDJC24300]
- National High Technology Research and Development Program 863 [2012AA02A508]
Ask authors/readers for more resources
Epidermal growth factor receptors (EGFR) expression is frequently amplified in human glioblastoma cells. Nimotuzumab, a monoclonal antibody (mAb) against EGFR, has been used globally in clinics as an anticancer agent. It is largely unknown whether the blockade of miR-21, a microRNA that is upregulated in glioma cells, could amplify the effects of nimotuzumab. Herein, we have demonstrated that miR-21 directly targets von Hippel-Lindau (VHL) and peroxisome-proliferator-activated receptor alpha (PPAR alpha) and that miR-21 regulates EGFR/AKT signaling through VHL/beta-catenin and the PPAR alpha/AP-1 axis. Further, the expression of miR-21 is regulated by EGFR via the activation of beta-catenin and AP-1. These data indicate that a feedback loop exists between miR-21 and EGFR. We also show that the combination of nimotuzumab and an inhibitor of miR-21 is superior to single-agent therapy. These results clarify a novel association between miR-21 and EGFR in the regulation of cancer cell progression. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available